Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARγ fusion protein thyroid carcinoma

Endocrinology

Volumn 152, Issue 11, 2011, Pages 4455-4465

  Dobson, Melissa E ^a   Diallo Krou, Ericka ^c   Grachtchouk, Vladimir ^b   Yu, Jingcheng ^a   Colby, Lesley A ^b   Wilkinson, John E ^b   Giordano, Thomas J ^a,b   Koenig, Ronald J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; PAX 8 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA FUSION PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIOGLITAZONE; PROTEIN KINASE B; TRANSCRIPTION FACTOR PAX8; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE DELETION; LIPID STORAGE; METASTASIS; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID ADENOMA; THYROID CARCINOMA; TRANSGENIC MOUSE;

ADENOCARCINOMA, FOLLICULAR; ADIPOGENESIS; ANIMALS; MICE; MICE, TRANSGENIC; ONCOGENE PROTEINS, FUSION; PAIRED BOX TRANSCRIPTION FACTORS; PPAR GAMMA; THIAZOLIDINEDIONES; THYROID GLAND; THYROID NEOPLASMS; TRANSLOCATION, GENETIC;

EID: 80054899975     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-1178     Document Type: Article

References (40)

1. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, Fletcher JA 2000 PAX8-PPARγ1 fusion oncogene in human thyroid carcinoma. Science 289:1357-1360 (Pubitemid 30656054)
2. Macchia PE, Lapi P, Krude H, Pirro MT, Missero C, Chiovato L, Souabni A, Baserga M, Tassi V, Pinchera A, Fenzi G, Grüters A, Busslinger M, Di Lauro R 1998 PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis. Nat Genet 19:83-86 (Pubitemid 28242030)
3. Mansouri A, Chowdhury K, Gruss P 1998 Follicular cells of the thyroid gland require Pax8 gene function. Nat Genet 19:87-90 (Pubitemid 28242031)
4. Esposito C, Miccadei S, Saiardi A, Civitareale D 1998 PAX 8 activates the enhancer of the human thyroperoxidase gene. Biochem J 331(Pt 1):37-40 (Pubitemid 28163954)
5. Ohno M, Zannini M, Levy O, Carrasco N, di Lauro R 1999 The paired-domain transcription factor Pax8 binds to the upstream enhancer of the rat sodium/iodide symporter gene and participates in both thyroid-specific and cyclic-AMP-dependent transcription. Mol Cell Biol 19:2051-2060 (Pubitemid 29098263)
6. Fabbro D, Pellizzari L, Mercuri F, Tell G, Damante G 1998 Pax-8 protein levels regulate thyroglobulin gene expression. J Mol Endocrinol 21:347-354 (Pubitemid 29005406)
7. Au AY, McBride C, Wilhelm Jr KG, Koenig RJ, Speller B, Cheung L, Messina M, Wentworth J, Tasevski V, Learoyd D, Robinson BG, Clifton-Bligh RJ 2006 PAX8-peroxisome proliferator-activated receptor γ (PPARγ) disrupts normal PAX8 or PPARγ transcriptional function and stimulates follicular thyroid cell growth. Endocrinology 147:367-376 (Pubitemid 43004290)
8. Gregory Powell J, Wang X, Allard BL, Sahin M, Wang XL, Hay ID, Hiddinga HJ, Deshpande SS, Kroll TG, Grebe SK, Eberhardt NL, McIver B 2004 The PAX8/PPARγ fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARγ inhibition. Oncogene 23:3634-3641 (Pubitemid 38658430)
9. Fujisawa T, Sugiyama M, Tomimoto A, Wada K, Endo H, Takahashi H, Yoneda K, Yoneda M, Inamori M, Saito S, Terauchi Y, Kadowaki T, Tsuchiya N, Nakagama H, Nakajima A 2008 Inhibition of peroxisome proliferator-activated receptor γ promotes tumorigenesis through activation of the β-catenin/T cell factor (TCF) pathway in the mouse intestine. J Pharmacol Sci 108:535-544
10. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, Kim PJ, Owens RJ, Lang NP 2007 Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 25:1476-1481 (Pubitemid 46733074)
11. Kato Y, Ying H, Zhao L, Furuya F, Araki O, Willingham MC, Cheng SY 2006 PPARγ insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-κB signaling pathway. Oncogene 25:2736-2747
12. Park JW, Zarnegar R, Kanauchi H, Wong MG, Hyun WC, Ginzinger DG, Lobo M, Cotter P, Duh QY, Clark OH 2005 Troglitazone, the peroxisome proliferator-activated receptor-γ agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 15:222-231 (Pubitemid 40418689)
13. Giordano TJ, Au AY, Kuick R, Thomas DG, Rhodes DR, Wilhelm Jr KG, Vinco M, Misek DE, Sanders D, Zhu Z, Ciampi R, Hanash S, Chinnaiyan A, Clifton-Bligh RJ, Robinson BG, Nikiforov YE, Koenig RJ 2006 Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARγ translocation. Clin Cancer Res 12:1983-1993
14. Lacroix L, Lazar V, Michiels S, Ripoche H, Dessen P, Talbot M, Caillou B, Levillain JP, Schlumberger M, Bidart JM 2005 Follicular thyroid tumors with the PAX8-PPARγ1 rearrangement display characteristic genetic alterations. Am J Pathol 167:223-231 (Pubitemid 40884783)
15. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R 1997 Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16:64-67 (Pubitemid 27198157)
16. Paes JE, Ringel MD 2008 Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol Metab Clin North Am 37:375-387 (Pubitemid 351698084)
17. Diallo-Krou E, Yu J, Colby LA, Inoki K, Wilkinson JE, Thomas DG, Giordano TJ, Koenig RJ 2009 Paired box gene 8-peroxisome proliferator-activated receptor-γ fusion protein and loss of phosphatase and tensin homolog synergistically cause thyroid hyperplasia in transgenic mice. Endocrinology 150:5181-5190
18. Pasca di Magliano M, Sekine S, Ermilov A, Ferris J, Dlugosz AA, Hebrok M 2006 Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes Dev 20:3161-3173 (Pubitemid 44790630)
19. Kusakabe T, Kawaguchi A, Kawaguchi R, Feigenbaum L, Kimura S 2004 Thyrocyte-specific expression of Cre recombinase in transgenic mice. Genesis 39:212-216 (Pubitemid 39079520)
20. Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H, Liu X, Wu H 2002 Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 32:148-149 (Pubitemid 34211723)
21. Dwight T, Thoppe SR, Foukakis T, Lui WO, Wallin G, Höög A, Frisk T, Larsson C, Zedenius J 2003 Involvement of the PAX8/ peroxisome proliferator-activated receptor γ rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab 88:4440-4445 (Pubitemid 37153755)
22. Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG, Leite V 2002 Expression of PAX8-PPARγ 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87:3947-3952 (Pubitemid 34879553)
23. Yeager N, Klein-Szanto A, Kimura S, Di Cristofano A 2007 Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis. Cancer Res 67:959-966
24. Okumura T 2010 Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs. J Gastroenterol 45:1097-1102
25. Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, Briggs M, Heyman R, Auwerx J 1998 Activation of the peroxisome proliferator-activated receptorγ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 4:1053-1057 (Pubitemid 28417338)
26. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA, Evans RM 1998 Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat Med 4:1058-1061 (Pubitemid 28417339)
27. Ikezoe T, Miller CW, Kawano S, Heaney A, Williamson EA, Hisatake J, Green E, Hofmann W, Taguchi H, Koeffler HP 2001 Mutational analysis of the peroxisome proliferator-activated receptor γgene in human malignancies. Cancer Res 61:5307-5310 (Pubitemid 32681569)
28. Burton JD, Goldenberg DM, Blumenthal RD 2008 Potential of peroxisome proliferator-activated receptor γ antagonist compounds as therapeutic agents for a wide range of cancer types. PPAR Res 2008: 494161
29. Schaefer KL, Wada K, Takahashi H, Matsuhashi N, Ohnishi S, Wolfe MM, Turner JR, Nakajima A, Borkan SC, Saubermann LJ Peroxisome proliferator- activated receptor γ inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res 65:2251-2259
30. Bojková B, Garajová M, Kajo K, Péc M, Kubatka P, Kassayová M, Kisková T, Orendás P, Ahlersová E, Ahlers I 2010 Pioglitazone in chemically induced mammary carcinogenesis in rats. Eur J Cancer Prev 19:379-384
31. Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T, Matsuhashi N, Kadowaki T, Ochiai M, Sekihara H, Nakagama H 2003 Peroxisome proliferator-activated receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 124:361-367 (Pubitemid 36169253)
32. Magenta G, Borenstein X, Rolando R, Jasnis MA 2008 Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3. BMC Cancer 8:47
33. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM 1998 Terminal differentiation of human breast cancer through PPARγ. Mol Cell 1:465-470 (Pubitemid 128378895)
34. Choi JH, Banks AS, Estall JL, Kajimura S, Boström P, Laznik D, Ruas JL, Chalmers MJ, Kamenecka TM, Blüher M, Griffin PR, Spiegelman BM 2010 Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5. Nature 466:451-456
35. Kebebew E, Lindsay S, Clark OH, Woeber KA, Hawkins R, Greenspan FS 2009 Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer. Thyroid 19:953-956
36. Debrock G, Vanhentenrijk V, Sciot R, Debiec-Rychter M, Oyen R, Van Oosterom A 2003 A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 89:1409-1412 (Pubitemid 37386592)
37. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM 1995 15-Deoxy-Δ12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83:803-812 (Pubitemid 3006324)
38. Hallenborg P, Jørgensen C, Petersen RK, Feddersen S, Araujo P, Markt P, Langer T, Furstenberger G, Krieg P, Koppen A, Kalkhoven E, Madsen L, Kristiansen K 2010 Epidermis-type lipoxygenase 3 regulates adipocyte differentiation and peroxisome proliferator-activated receptor γ activity. Mol Cell Biol 30:4077-4091
39. Itoh T, Fairall L, Amin K, Inaba Y, Szanto A, Balint BL, Nagy L, Yamamoto K, Schwabe JW 2008 Structural basis for the activation of PPARγ by oxidized fatty acids. Nat Struct Mol Biol 15:924-931
40. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM 1995 A prostaglandin J2 metabolite binds peroxisome proliferator- activated receptor γ and promotes adipocyte differentiation. Cell 83:813-819 (Pubitemid 3006325)